Vioix H - Search Results

1

Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.

Kato T, Yang JC, Ahn MJ, Sakai H, Morise M, Chen YM, Han JY, Yang JJ, Zhao J, Hsia TC, Berghoff K, Bruns R, Vioix H, Lang S, Johne A, Le X, Paik PK. Kato T, et al. Among authors: vioix h. Br J Cancer. 2024 Jun;130(10):1679-1686. doi: 10.1038/s41416-024-02615-9. Epub 2024 Apr 4. Br J Cancer. 2024. PMID: 38575731 Free PMC article. Clinical Trial.

2

Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations.

Paik PK, Pfeiffer BM, Vioix H, Garcia A, Postma MJ. Paik PK, et al. Among authors: vioix h. Adv Ther. 2022 Jul;39(7):3159-3179. doi: 10.1007/s12325-022-02163-9. Epub 2022 May 11. Adv Ther. 2022. PMID: 35543963 Free PMC article.

3

Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B.

Le X, Paz-Ares LG, Van Meerbeeck J, Viteri S, Galvez CC, Smit EF, Garassino M, Veillon R, Baz DV, Pradera JF, Sereno M, Kozuki T, Kim YC, Yoo SS, Han JY, Kang JH, Son CH, Choi YJ, Stroh C, Juraeva D, Vioix H, Bruns R, Otto G, Johne A, Paik PK. Le X, et al. Among authors: vioix h. Cell Rep Med. 2023 Nov 21;4(11):101280. doi: 10.1016/j.xcrm.2023.101280. Epub 2023 Nov 8. Cell Rep Med. 2023. PMID: 37944528 Free PMC article.

4

Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK.

Batteson R, Hook E, Wheat H, Hatswell AJ, Vioix H, McLean T, Alexopoulos ST, Baijal S, Paik PK. Batteson R, et al. Among authors: vioix h. Target Oncol. 2024 Mar;19(2):191-201. doi: 10.1007/s11523-024-01038-z. Epub 2024 Mar 16. Target Oncol. 2024. PMID: 38492157 Free PMC article.

5

MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.

Mazieres J, Vioix H, Pfeiffer BM, Campden RI, Chen Z, Heeg B, Cortot AB. Mazieres J, et al. Among authors: vioix h. Clin Lung Cancer. 2023 Sep;24(6):483-497. doi: 10.1016/j.cllc.2023.06.008. Epub 2023 Jun 18. Clin Lung Cancer. 2023. PMID: 37451931 Free article. Review.

6

Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States.

Stargardter M, McBride A, Tosh J, Sachdev R, Yang M, Ambavane A, Mittal M, Vioix H, Liu FX. Stargardter M, et al. Among authors: vioix h. J Med Econ. 2021 Jan-Dec;24(1):816-827. doi: 10.1080/13696998.2021.1942017. J Med Econ. 2021. PMID: 34126842 Free article.

7

Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.

Zheng Y, Vioix H, Liu FX, Singh B, Sharma S, Sharda D. Zheng Y, et al. Among authors: vioix h. Future Oncol. 2022 Feb;18(4):505-518. doi: 10.2217/fon-2021-1040. Epub 2021 Dec 6. Future Oncol. 2022. PMID: 34865516 Free article. Review.

8

Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping.

Yang M, Vioix H, Hook ES, Hatswell AJ, Batteson RL, Gaumond BR, O'Brate A, Popat S, Paik PK. Yang M, et al. Among authors: vioix h. Value Health. 2023 Aug;26(8):1155-1163. doi: 10.1016/j.jval.2023.02.007. Epub 2023 Feb 18. Value Health. 2023. PMID: 36805576 Free article.

9

Cost-consequence analysis of COPD treatment according to NICE and GOLD recommendations compared with current clinical practice in the UK.

Wright A, Vioix H, de Silva S, Langham S, Cook J, Capstick T, Quint JK. Wright A, et al. Among authors: vioix h. BMJ Open. 2022 Jun 3;12(6):e059158. doi: 10.1136/bmjopen-2021-059158. BMJ Open. 2022. PMID: 36691251 Free PMC article.

10

Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non-Small Cell Lung Cancer Harboring Mesenchymal-Epithelial Transition Exon 14 Skipping.

Yang M, Vioix H, Sachdev R, Stargardter M, Tosh J, Pfeiffer BM, Paik PK. Yang M, et al. Among authors: vioix h. Value Health. 2023 Apr;26(4):487-497. doi: 10.1016/j.jval.2022.11.018. Epub 2022 Dec 8. Value Health. 2023. PMID: 36503033 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page